SCHEMBL9926520

SCHEMBL9926520

Cc1cc(Cl)ccc1CC(=O)NCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
ALDH1A1 P00352 3/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
SMN1; SMN2 Q16637 3/20 0.54
HPGD P15428 1/20 0.54
P2RX7 Q99572 2/20 0.54
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
HSD17B2 P37059 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.52
ERCC1 P07992 1/20 0.51
ERCC4 Q92889 1/20 0.51
LMNA P02545 3/20 0.50
CYP3A4 P08684 2/20 0.49
F2 P00734 1/20 0.49
MAPT P10636 1/20 0.49
PKM P14618 1/20 0.49
CYP1A2 P05177 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9926533 0.86 SMN1; SMN2 (0.66) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL9926518 0.84 NPC1 (0.57) MEN1KMT2ANPC1SMN1; SMN2ERCC1
SCHEMBL9926561 0.84 KMT2A (0.65) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL25046059 0.82 ALDH1A1 (0.65) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL9926586 0.81 HPGD (0.50) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL9926519 0.80 POLB (0.58) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL28992291 0.79 ALDH1A1 (0.68) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL8651253 0.79 P2RX7 (0.50) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL9926464 0.79 P2RX7 (0.51) P2RX7
SCHEMBL5860896 0.79 ALDH1A1 (0.73) MEN1KMT2AALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS MDM4, MDM2, TP53 MEN1 510/4885KMT2A 1512/4885ALDH1A1 4361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.